Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
Clinical trial NCT02498912 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT02498912
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-01
- Primary completion
- 2026-08-01
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.